InDex Pharmaceuticals

OverviewSuggest Edit

InDex Pharmaceuticals Holding is a company that focuses on immunological diseases. It develops cobitolimod, a medication for patients with moderate-to-severe active ulcerative colitis. In addition, the company provides a platform for patent protected discovery stage substances, which can be used in treatment of various immunological diseases.
TypePublic
Founded2000
Websiteindexpharma.com

Latest Updates

Employees (est.) (Dec 2018)7
Share Price (Jul 2020)KR6.3 (+6%)
Cybersecurity ratingAMore

InDex Pharmaceuticals Financials and Metrics

InDex Pharmaceuticals Revenue

Market capitalization (27-Apr-2020)

621.5m

Closing stock price (27-Apr-2020)

6.9
InDex Pharmaceuticals's current market capitalization is kr621.5 m.
Show all financial metrics

InDex Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

InDex Pharmaceuticals Online and Social Media Presence

Embed Graph

InDex Pharmaceuticals News and Updates

InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation

STOCKHOLM, March 31, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that SEK 2.0 million has been granted from Sweden's innovation agency Vinnova to develop new, more effective and safer treatments for inflammatory diseases. The grant from Vinnova within the...

InDex Pharmaceuticals Frequently Asked Questions

  • When was InDex Pharmaceuticals founded?

    InDex Pharmaceuticals was founded in 2000.

  • How many employees does InDex Pharmaceuticals have?

    InDex Pharmaceuticals has 7 employees.

  • Who are InDex Pharmaceuticals competitors?

    Competitors of InDex Pharmaceuticals include GT Biopharma, Humanigen and Selecta Biosciences.